Retatrutide produces up to 20.8% weight loss in obesity with type 2 diabetes
AJMC reports the Eli Lilly triple agonist's results in patients who also have type 2 diabetes, a group that typically loses less weight on incretin drugs.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 10:19 ETSource: AJMC
The wire
- 01AJMC reports retatrutide yielded up to 20.8% mean weight loss in people with obesity and type 2 diabetes.
- 02Patients with type 2 diabetes generally see smaller reductions than those without, so the figure is a benchmark clinicians will compare against semaglutide and tirzepatide.
- 03Dosing detail, trial duration, comparator arms and tolerability were not detailed in the report; full published results are needed before drawing conclusions.
From the source
Read at ajmc.comRetatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
